Literature DB >> 17045775

In-vitro human skin penetration of the fragrance material geranyl nitrile.

K R Brain1, D M Green, J Lalko, A M Api.   

Abstract

In-vitro human skin permeation and distribution of geranyl nitrile (GN) was determined using epidermal membranes following application (5 microl/cm(2)) in 70% ethanol, under non-occlusive conditions, at maximum in-use concentration (1%). Permeation was measured (12 time-points over 24 h) using 6% (w/v) Oleth-20 in pH 7.4 phosphate buffered saline as receptor. Permeation of reference benzoic acid was assessed using the same skin donors. Overall recovery of GN at 24 h was low (14.1+/-0.4%) due to evaporation. Evaporative loss of GN from polytetrafluoroethylene (PTFE) sheet, under the same conditions was rapid (93% over 24h) although this overestimated loss during permeation where evaporation competed with uptake. At 24 h, 1.89+/-0.15 microg/cm(2) GN, (3.74+/-0.30% of applied dose) (mean+/-standard error, SE, n=12), had permeated. Following rapid initial permeation, the absorption plateaued due to depletion. Levels of GN in the epidermis (plus any remaining stratum corneum after tape stripping), filter paper membrane support and receptor fluid were combined (as per SCCNFP guidelines) to produce a total absorbed dose value of 4.72+/-0.32%. Systemic exposure resulting from the use of GN as a fragrance ingredient, under unoccluded conditions, would be low based on the currently reported use levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045775     DOI: 10.1016/j.tiv.2006.08.005

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  1 in total

1.  ATR-FTIR and Raman spectroscopic investigation of the electroporation-mediated transdermal delivery of a nanocarrier system containing an antitumour drug.

Authors:  Boglárka Balázs; Péter Sipos; Corina Danciu; Stefana Avram; Codruta Soica; Cristina Dehelean; Gábor Varju; Gábor Erős; Mária Budai-Szűcs; Szilvia Berkó; Erzsébet Csányi
Journal:  Biomed Opt Express       Date:  2015-12-08       Impact factor: 3.732

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.